Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dihematoporphyrin derivative

PreclinicalSmall molecule

MMedical College of Hampton Roads

Dihematoporphyrin derivative is one of 2 small molecule programs targeting Corneal Neovascularization. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal NeovascularizationActive, not recruiting

Corneal NeovascularizationPreclinical

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Corneal Neovascularization

#DrugCompanyPhaseTrials

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Dihematoporphyrin derivative

MMedical College of Hampton Roads

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Neovascularization1 trial

Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization

Completed·MMedical College of Hampton Roads·N/A·NCT00004430·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dihematoporphyrin derivative. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dihematoporphyrin derivative compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dihematoporphyrin derivative. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Hampton Roads company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical College of Hampton Roads

Related News